When do the BENADRYL PRESERVATIVE FREE patents expire, and when will generic BENADRYL PRESERVATIVE FREE be available?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mcneil Cons	BENADRYL PRESERVATIVE FREE	diphenhydramine hydrochloride	INJECTABLE;INJECTION	009486-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 8, 2026

BENADRYL PRESERVATIVE FREE investment scenario and IP exclusivity fundamentals

Benadryl Preservative Free is a branded, OTC/directed-drug legacy product line built around diphenhydramine hydrochloride (HCl) and positioned around “preservative-free” packaging/form-factor rather than a new molecular entity. The investment thesis is constrained by near-certain generic availability of diphenhydramine HCl and the absence of durable, molecule-level exclusivity typical of patented Rx launches. Competitive advantage tends to be logistics, supply reliability, label claims, and formulation/packaging defensibility rather than long runway patent life.

Bottom line: treat the franchise as a mature, low-innovation asset with limited patent-backed pricing power. Any margin lift depends on (1) sustained branded OTC differentiation in specific presentations (single-ingredient diphenhydramine, preservative-free pediatric/clinical use cases), (2) exclusionary IP that is likely narrow if present, and (3) contracting leverage with wholesalers, PBMs (limited for OTC), hospitals, and institutional buyers. Without verified product-specific patent estate data for the exact “preservative free” presentation, molecule-level exclusivity cannot be assumed.

What is BENADRYL PRESERVATIVE FREE and what is the underlying active ingredient economics?

Answer: BENADRYL Preservative Free is a diphenhydramine HCl product line that competes in the long-established first-generation antihistamine class.

Product characteristics that shape fundamentals

Active ingredient: diphenhydramine hydrochloride (HCl)
Therapeutic class: first-generation H1 antihistamine (OTC; also used in clinical settings for allergic symptoms and as an antihistamine adjunct depending on label)
Differentiator claim: “preservative-free,” usually tied to formulation excipients and/or packaging choices intended to reduce preservative exposure for sensitive uses

How that changes the investment model

Brand vs patent moat: diphenhydramine HCl is a mature API with broad generic penetration.
Demand behavior: OTC antihistamines are price- and promotion-sensitive; branded differentiation is typically not enough to sustain premium pricing without supply stability or locked-in purchasing channels.
Key cost drivers: API sourcing, sterile vs non-sterile manufacturing (presentation-dependent), packaging, and regulatory/label maintenance rather than R&D.

What patents protect diphenhydramine hydrochloride and “preservative-free” BENADRYL presentations?

Answer: For diphenhydramine HCl, molecule-level patents from earlier eras are generally expired or near-expired, and the practical protectable area is limited to specific formulation, manufacturing, packaging, or method-of-use patents tied to the exact presentation.

Where patent value can still exist (narrowly)

Formulation patents: preservative-free excipient selection, compatibility, stability, and shelf-life improvements
Manufacturing-method patents: process steps that reduce impurities or maintain preservative-free status
Packaging patents: container closure system or delivery format that supports stability without added preservatives
Labeling/indication patents: less common for OTC antihistamines unless tied to specific labeled uses

What investors should treat as the core IP risk

Generic entry risk: in mature APIs, generic manufacturers can design around without needing to copy the brand’s formulation unless an enforceable, presentation-specific patent exists.
Patent scope: even when formulation patents exist, they often cover a specific composition or manufacturing step. Generic “equivalents” may avoid literal infringement.

(No product-specific patent list for “BENADRYL Preservative Free” is provided in the prompt, so an exact patent inventory cannot be produced here.)

When does BENADRYL PRESERVATIVE FREE lose exclusivity?

Answer: For diphenhydramine HCl, exclusivity is generally dominated by presentation-specific patents and regulatory exclusivity for that presentation, not by molecule-level exclusivity. For most diphenhydramine HCl OTC formulations, exclusivity is effectively long over.

Practical timing framework for an OTC diphenhydramine franchise

If presentation-specific patents exist: generic knockouts usually occur after patent expiry plus any regulatory or settlement carve-outs.
If no enforceable patent estate exists: generic and private label competition compress margins immediately in normal market cycles.
What to monitor instead of “exclusivity”:
- Supply allocation events and shortages (can temporarily support brand pricing)
- Wholesaler/purchaser switching behavior (promotional calendar)
- Institutional purchasing of preservative-free versions (hospital formularies)

(Exact exclusivity dates require a product-specific Orange Book/patent listing record, which is not provided in the prompt.)

What is the Orange Book status of BENADRYL PRESERVATIVE FREE?

Answer: Orange Book status applies to approved FDA drug products with listed patents and exclusivity. BENADRYL Preservative Free, as an OTC product, may or may not have listed patents in the Orange Book depending on whether it is an FDA-approved drug product subject to patent listing for that specific presentation.

Investor implication

If listed patents are absent or expired: generic risk is structurally high.
If patents are listed and still active: the investment case shifts toward litigating or licensing rather than assuming brand-level pricing power.

(A product-specific Orange Book extract is not included in the prompt, so no definitive status can be provided.)

How strong is the patent estate for “preservative-free” diphenhydramine products?

Answer: The likely profile for mature diphenhydramine APIs is a weak molecule-level estate and, at best, narrow protection around specific preservative-free formulations and manufacturing/packaging methods.

Patent strength signals to look for (deal/investment checklist)

Independent claims count and breadth (composition vs process vs use)
Family size and remaining life
Claim-to-product mapping to the exact marketed strength, dosage form, and container closure
History of generic challenges (signals whether patents are considered enforceable)

(No patent family data is provided in the prompt.)

What generic entry risks exist for BENADRYL PRESERVATIVE FREE?

Answer: Generic entry risk is high given the maturity of diphenhydramine HCl and the typical ease of competing OTC antihistamines once patent coverage is absent or narrow.

Typical OTC competition mechanics

Immediate substitution: pharmacists and consumers often substitute generics or store brands if labeling and dosing match.
Channel-driven pricing: wholesalers and mass retail drive margin compression.
Promotion cycles: brand manufacturers must spend to defend share.

Where preservative-free could still matter competitively

Clinical/hospital purchase logic: preservative-free requirements can restrict substitution.
Patient adherence: formulation tolerability differences can support repeat purchasing in certain segments.

(Quantifying substitution risk requires sales and channel data not provided in the prompt.)

What formulation and delivery-system patents could cover “preservative-free” versions?

Answer: Protectable space usually clusters in:

Composition/excipient selection that achieves stability without preservatives
pH/tonicity/surfactant systems that maintain preservative-free stability
Container closure system and leachables that reduce the need for preservatives
Manufacturing controls that reduce microbial risk without preservatives

Why this matters for investment

Narrow formulation patents can block direct copycats but often do not stop market entry from “functionally equivalent” generic formulations.
The economic value of such patents usually shows up as higher gross margin only if the brand’s formulation is hard to replicate to FDA-grade specifications.

(No formulation patent list for the specific product is available from the prompt.)

What patent litigation affects diphenhydramine preservative-free products?

Answer: For mature APIs, litigation usually centers on formulation/process patents and generic challenge strategy rather than the underlying drug substance.

Investor relevance

Litigation can be a value transfer mechanism: settlements, consent judgments, or licensing can temporarily sustain branded pricing.
Litigation can also be a downside trigger: adverse rulings accelerate generic penetration.

(No litigation docket or case list is provided in the prompt.)

What FDA regulatory status applies to BENADRYL PRESERVATIVE FREE (OTC pathway and labeling)?

Answer: OTC antihistamine products are marketed under the OTC regulatory framework with FDA-required labeling and manufacturing compliance. If the product is an OTC drug product, the key compliance burdens are GMP and labeling conformity rather than novel clinical approval.

What investors should monitor

GMP quality events and recall risk (OTC still has meaningful manufacturing scrutiny)
Labeling updates that can change consumer demand and channel listing
Supply chain reliability of packaging that preserves “preservative-free” integrity

(No product-level FDA event history is provided in the prompt.)

Which companies are challenging or competing against BENADRYL PRESERVATIVE FREE?

Answer: Competition is typically dominated by:

Generic manufacturers of diphenhydramine HCl OTC products
OTC contract manufacturers and private label suppliers
Brand competitors within antihistamine OTC class

Competitive landscape that matters

Private label penetration at mass retailers and pharmacy chains
Hospital/clinic procurement of preservative-free formats when required
Shelf space economics and wholesaler incentives

(No competitor list tied to the exact preservative-free presentation is provided in the prompt.)

How does BENADRYL PRESERVATIVE FREE compare with competing OTC diphenhydramine products?

Answer: The primary basis of differentiation is the “preservative-free” attribute and presentation-specific tolerability/use-case, not therapeutic superiority.

Competitive comparison dimensions

Price-to-effectiveness: generics usually dominate on cost
Clinical preference: preservative-free formulations can be required by workflow in certain settings
Availability: supply continuity can drive brand share in shortage periods

(No side-by-side SKU pricing or NDC-level market share data is provided in the prompt.)

Revenue exposure: where does the economic thesis break down?

Answer: The thesis breaks down when branded pricing exceeds generic parity without an enforceable, remaining exclusivity or a strong channel lock-in.

High-risk revenue scenarios for OTC diphenhydramine franchises

Rapid private label price compression
Loss of contract/hospital formulary position for preservative-free format
Supply-driven brand substitution by purchasers when alternative SKUs are available

What supports revenue in a mature OTC market

Differentiated buyer requirement (preservative-free demand)
Limited substitute availability during manufacturing capacity disruptions
Promotional intensity that maintains share in key retail channels

(No unit sales or gross margin data is included in the prompt.)

Key Takeaways

BENADRYL Preservative Free is a mature diphenhydramine HCl OTC franchise where molecule-level exclusivity is not the foundation of investment value.
The defendable edge, if any, is likely narrow and presentation-specific: preservative-free formulation, manufacturing, and packaging.
Generic entry risk is structurally high unless product-specific patents remain enforceable and cover the exact marketed presentation.
The investment case should be treated as a channel and supply-driven business with limited long-run patent insulation unless an active, enforceable patent estate exists for the preservative-free SKU.

FAQs

1) Is BENADRYL Preservative Free a patented drug product?
It is typically not a molecule-level patented asset; any patent protection would need to be tied to the specific preservative-free presentation (formulation/process/packaging).

2) Can generics be marketed as “preservative-free” diphenhydramine?
Yes, generally by designing alternative preservative-free formulations and meeting FDA quality requirements unless blocked by enforceable, presentation-specific patents.

3) What is the biggest driver of pricing for an OTC preservative-free antihistamine?
Channel pricing and promotion, with brief support from supply constraints or buyer-specific preservative-free requirements.

4) Does Orange Book exclusivity meaningfully protect OTC diphenhydramine products?
Usually not over long horizons for mature diphenhydramine. The only meaningful protection is if product-specific patents listed for the exact presentation are still active.

5) What is the main diligence item for an investment in this product line?
A verified, SKU-level patent and regulatory mapping for the exact “preservative-free” strength/dosage form, plus evidence of channel lock-in where preservative-free status is a purchasing constraint.

References

No sources were provided in the prompt, and no verified Orange Book, patent, FDA listing, or litigation records specific to “BENADRYL Preservative Free” were supplied.

BENADRYL PRESERVATIVE FREE Drug Patent Profile

When do Benadryl Preservative Free patents expire, and what generic alternatives are available?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Benadryl Preservative Free

AI Deep Research

Questions you can ask:

Summary for BENADRYL PRESERVATIVE FREE

US Patents and Regulatory Information for BENADRYL PRESERVATIVE FREE